Elucidation of Interferon Sensitivity Determining Region in Hepatitis C Virus Genome

丙型肝炎病毒基因组中干扰素敏感性决定区的阐明

基本信息

  • 批准号:
    06670525
  • 负责人:
  • 金额:
    $ 1.47万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1994
  • 资助国家:
    日本
  • 起止时间:
    1994 至 1995
  • 项目状态:
    已结题

项目摘要

We have previously demonstrated that sensitivity to interferon is different among hepatitis C virus (HCV) quasispecies simultaneously detected in same individuals and that interferon-resistant HCV quasispecies are selected during the treatment. To determine the genetic basis of their resistance to interferon, HCV genotype-1b was obtained from serum of three patients before and during interferon therapy, and their full-length nucleotide and deduced amino acid sequences were determined. Comparison of the paris of interferon-resistant and interferon-sensitive HCV isolates in respective individuals demonstrated clusters of amino acid differences in the C-terminal half of the NS5A region (codon 2154-2383), which contained a common unique amino acid difference at codon 2218. Additional sequence data of the C-terminal half of the NS5A region obtained from six interferon-resistant and nine interferon-sensitive HCV confirmed the exclusive existence of missense mutations in a 40 amino acid stret … More ch of the NS5A region around codon 2218 (from codon 2209 to codon 2248) in interferon-sensitive HCV.On the other hand, this region of interferon-resistant HCV was identical to that of prototype HCV genotype-1b (HCV-J,HCV-JTa or HC-J4). We designated this region as the interferon sensitivity determining region. Thus, HCV genotype-1b with the prototype-interferon sensitivity determining region appears to be interferon-resistant strains. The specific nature of these mutations would make it possible to predict prognostic effects of interferon treatment.Subsequently, we evaluated the possibility for predicting the response to interferon by examining the NS5A2209-2248 of pretherapy HCV.Eighty-four patients with chronic hepatitis C infected with HCV-1b were treated with high doses of interferon-alpha. The deduced amino acid sequence of the NS5A2209-2248 was determined by direct sequencing of the NS5A2209-2248 amplified from serum RNA by polymerase chain reaction. Complete responses with negative serum HCV-RNA for six months after the cessation of interferon were observed in 0 percent of 30 patients with the wild type NS5A2209-2248 (no amino acid substitution compared to the prototype HCV-1b), 13 percent of 38 patients with the intermediate type (1-3 amino acid substitutions), and 100percent of 16 patients with the mutant type (4 or more amino acid substitutions), indicating that the mutant type was significantly associated with the complete response (P<0.001). Although serum HCV-RNA level was lower in the mutant type than the others (P<0.001), multivariate analyzes revealed that the number of amino acid substitutions in the NS5A2209-2248 was the only independent predictor of the complete response (odds ratio 5.4, P=0.007). Responses to interferon are closely related to the structure of the NS5A2209-2248, which is predictive for the outcome of interferon therapy in chronic HCV-1b infection. Less
我们之前已经证明,在同一个体中同时检测到的丙型肝炎病毒(HCV)准种对干扰素的敏感性不同,并且在治疗期间选择干扰素耐药的HCV准种。为了确定其对干扰素耐药的遗传基础,从3例患者在干扰素治疗前和治疗期间的血清中提取HCV基因型1b,并测定其全长核苷酸和推断氨基酸序列。在不同个体中比较干扰素耐药和干扰素敏感HCV分离株,发现在NS5A区c端一半(密码子2154-2383)存在氨基酸簇差异,其中密码子2218处存在共同的独特氨基酸差异。从6例干扰素耐药型和9例干扰素敏感型丙型肝炎病毒中获得的NS5A c端一半序列数据证实,在干扰素敏感型丙型肝炎病毒中,在密码子2218附近(从密码子2209到密码子2248)的40个氨基酸序列中,存在更多的错义突变。另一方面,干扰素耐药HCV的这一区域与原型HCV基因型1b (HCV- j、HCV- jta或HC-J4)相同。我们将该区域指定为干扰素敏感性决定区。因此,具有原型干扰素敏感性决定区域的HCV基因型1b似乎是干扰素耐药菌株。这些突变的特殊性使得预测干扰素治疗的预后效果成为可能。随后,我们通过检测治疗前HCV的NS5A2209-2248来评估预测干扰素应答的可能性。84例感染HCV-1b的慢性丙型肝炎患者接受高剂量干扰素- α治疗。采用聚合酶链反应对从血清RNA中扩增的NS5A2209-2248进行直接测序,确定了NS5A2209-2248的氨基酸序列。30例野生型NS5A2209-2248(与原型HCV-1b相比没有氨基酸替代)患者中有0%的人在停止干扰素治疗后6个月内血清HCV-RNA呈阴性,38例中间型(1-3个氨基酸替代)患者中有13%,16例突变型(4个或更多氨基酸替代)患者中有100%的人完全缓解。表明突变型与完全缓解显著相关(P<0.001)。虽然突变型患者的血清HCV-RNA水平低于其他突变型患者(P<0.001),但多因素分析显示,NS5A2209-2248中氨基酸替换的数量是完全缓解的唯一独立预测因子(优势比5.4,P=0.007)。对干扰素的应答与NS5A2209-2248的结构密切相关,可预测慢性HCV-1b感染干扰素治疗的结果。少

项目成果

期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nobuyuki Enomoto: "Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b." Journal of Clinical Investigation. 95. 224-30 (1995)
Nobuyuki Enomoto:“干扰素敏感型和耐药型丙型肝炎病毒 1b 的全长序列比较。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nobuyuki Enomoto: "Comparison of full-length sequences of interferon-sensitive and vesistant hepatitis C vines 1b." Journal of Clinical Investigation. 95. 224-230 (1995)
Nobuyuki Enomoto:“干扰素敏感型和持续性丙型肝炎藤 1b 全长序列的比较。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nobuyuki Enomoto: "Mutations in the uonsturctral protein 5A gene and response to interferon in patients with chronic hepatitis C uvrus 1b infection" New England Journal of Medicine. 334. 77-81 (1996)
Nobuyuki Enomoto:“慢性丙型肝炎 uvrus 1b 感染患者的非结构蛋白 5A 基因突变和对干扰素的反应”《新英格兰医学杂志》。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nobuyuki Enomoto: "Matatious in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C vines 1b infection-" New England Journal of Medicine. 334. 77-81 (1996)
Nobuyuki Enomoto:“慢性丙型肝炎藤 1b 感染患者的非结构蛋白 5A 基因的 Matatious 和对干扰素的反应 -”《新英格兰医学杂志》。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nobuyuki,Enomoto: "Companison of full-length sequences of interferon-sensitive and vesistant hepatitis Cvinnlb." :Journal of Clinical Investigation. 95. 224-30 (1995)
Nobuyuki,Enomoto:“干扰素敏感型和持续性肝炎 Cvinnlb 的全长序列的对照。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ENOMOTO Nobuyuki其他文献

ENOMOTO Nobuyuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ENOMOTO Nobuyuki', 18)}}的其他基金

Next-generation sequence of cancer-related genes in digestive organ cancers using clinical samples
使用临床样本对消化器官癌症中的癌症相关基因进行下一代序列
  • 批准号:
    26670380
  • 财政年份:
    2014
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Clarifying the pathogenesis of chronic hepatitis C through comprehensive genetic analyses of the virus and host using next-generation sequencer
使用下一代测序仪对病毒和宿主进行全面的遗传分析,阐明慢性丙型肝炎的发病机制
  • 批准号:
    23390195
  • 财政年份:
    2011
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis ofchronic viral hepaptis by the large-scale next generation sequeincing
大规模二代测序分析慢性病毒性肝炎
  • 批准号:
    21659186
  • 财政年份:
    2009
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Comprehensive analysis of chronic hepatitis C by large-scale viral genome wide analysis
通过大规模病毒全基因组分析对慢性丙型肝炎进行综合分析
  • 批准号:
    20390206
  • 财政年份:
    2008
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis of anti-interferon mechanism by HCV NS5A protein using HCV replicon system
利用HCV复制子系统分析HCV NS5A蛋白抗干扰素机制
  • 批准号:
    14370175
  • 财政年份:
    2002
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of anti-HCV therapy the regulation of NS5A function
抗HCV疗法的发展NS5A功能的调节
  • 批准号:
    12557053
  • 财政年份:
    2000
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis of liver diesease related gene expression using subtraction cloning
消减克隆技术分析肝脏疾病相关基因表达
  • 批准号:
    12670467
  • 财政年份:
    2000
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Function of HCV NS5A protein and the mechanism of interferon resistance
HCV NS5A蛋白的功能及干扰素抵抗机制
  • 批准号:
    10670456
  • 财政年份:
    1998
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

系统性探索不同N-glycan修饰对Interferonβ活性和稳定性影响
  • 批准号:
    21877063
  • 批准年份:
    2018
  • 资助金额:
    61.4 万元
  • 项目类别:
    面上项目
糖药物蛋白Interferonβ N-glycan的均一、人源化改造
  • 批准号:
    81102361
  • 批准年份:
    2011
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Identification of pathogenesis-promoting interferon-stimulated genes and development of regulatory strategies in mature B-cell tumors
成熟 B 细胞肿瘤中干扰素刺激促进发病基因的鉴定和调控策略的开发
  • 批准号:
    23K15330
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of Interferon-Gamma / Interleukin-12 Axis in Metabolic Liver Disease
干扰素-γ/白介素-12 轴在代谢性肝病中的作用
  • 批准号:
    10735419
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells
阐明骨髓增殖性肿瘤干细胞对干扰素-α的治疗耐药机制
  • 批准号:
    10736872
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
METABOLIC IMPACTS OF TYPE II INTERFERON SIGNALS IN OBESITY
II 型干扰素信号对肥胖的代谢影响
  • 批准号:
    10775353
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
Regulation and Manipulation of Oral Type III Interferon Responses by Porphyromonas gingivalis
牙龈卟啉单胞菌对口腔 III 型干扰素反应的调节和操纵
  • 批准号:
    10595198
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
Role of type I interferon signaling in the murine typhoid model
I 型干扰素信号在小鼠伤寒模型中的作用
  • 批准号:
    478962
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Operating Grants
Identification of interferon stimulated genes that control Toxoplasma in pig macrophages
猪巨噬细胞中控制弓形虫的干扰素刺激基因的鉴定
  • 批准号:
    BB/W014807/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Research Grant
Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic Sclerosis
干扰素调节因子 7 将干扰素通路激活与系统性硬化症中过度的纤维化反应联系起来
  • 批准号:
    10682192
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
Elucidating the role of type I interferon signaling and macrophage-derived inflammation in the juvenile host with viral pneumonia
阐明 I 型干扰素信号传导和巨噬细胞衍生炎症在病毒性肺炎幼年宿主中的作用
  • 批准号:
    10651426
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
Epigenetic regulation of cell-autonomous type I interferon responses in trophoblast
滋养层细胞自主 I 型干扰素反应的表观遗传调控
  • 批准号:
    MR/X008487/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了